Navigation Links
Vermillion Appoints Bruce A. Huebner as Interim Chief Executive Officer
Date:11/27/2012

AUSTIN, Texas, Nov. 27, 2012 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML), a molecular diagnostics company focused on ovarian cancer and vascular medicine, appointed director Bruce A. Huebner as interim chief executive officer. He succeeds Gail S. Page, who will assist in the transition and serve as a strategic advisor to the company as requested by its board of directors. Huebner will continue to serve on Vermillion's board of directors.

As previously announced, the company's board formed a succession committee of independent directors to oversee the process of identifying and selecting a new CEO. It has also retained a leading executive search firm with experience in CEO transitions to advise the board on potential candidates.

"With more than 37 years of diagnostic industry experience and leadership, as well as serving on a special Vermillion board committee that evaluates marketing strategies for OVA1®, Bruce will provide seasoned leadership as our interim CEO," said James S. Burns, the company's chairman of the board. "He will actively manage the business and ensure continuity of operations, as our succession committee searches for a new CEO who will take the company to its next level of growth and development.

"I would also like to thank Gail for the leadership and dedication that she has provided in bringing OVA1 to market and a pipeline of products to improve women's health. We look forward to consulting with Gail in the coming months as we continue to build advocacy for our ovarian cancer franchise among gynecologists and women's health groups."

Huebner has executive management experience in multiple clinical diagnostic companies, including Osmetech Molecular Diagnostics, Nanogen and Gen-Probe. While serving as president of Osmetech, he successfully established the company as a fully integrated business, obtaining FDA clearance for fo
'/>"/>

SOURCE Vermillion, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Delaware Court of Chancery Dismisses Vermillion Dissident Shareholder Suit with Prejudice
2. Vermillion Reports Third Quarter 2012 Results
3. Vermillion Sets Third Quarter 2012 Conference Call for Monday, November 12, 2012 at 4:30 p.m. ET
4. Vermillion to Present at the 2012 Gateway Conference on September 6
5. Vermillion Reports Second Quarter 2012 Results
6. Vermillion Announces Positive Top-Line Results from the OVA500 Multi-Center Study Led by UC Irvine
7. Vermillion PAD Intended Use Study Presented at Society for Vascular Medicine 23rd Annual Scientific Sessions
8. Vermillion Announces CEO Succession Plan
9. Vermillion Sets First Quarter 2012 Conference Call for Tuesday, May 15, 2012 at 4:30 p.m. ET
10. Saladax Biomedical, Inc. Appoints Mark D. Myslinski as Chief Commercial Officer
11. Positron Appoints Charles Conroy As Chief Operating Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014 /PRNewswire-iReach/ -- Market Research ... Industry, 2009-2019 is a professional and in-depth market ... Scanner industry . The report firstly reviews the ... classification, application and manufacturing technology. The report then ... Crystallography Scanner listing their product specification, capacity, Production ...
(Date:8/29/2014)... 2014 The clinical and medical insights provided ... between a product,s success or failure. Despite this, many ... targets – and then to coordinate activities and outreach ... upon which successful KOL engagement rests. ... internal inconsistencies in their KOL management systems and are ...
(Date:8/29/2014)... /PRNewswire-iReach/ -- SAM Medical Products Implements Voluntary Recall ... Junctional Tourniquet.  Photo - ... announced today that it has begun notifying customers ... issue with a clip used to secure the ... the SAM Junctional Tourniquet (SJT).  The company discovered ...
Breaking Medicine Technology:X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 2X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 3X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 4X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 5Implementing a Strategic Thought Leader Management & Engagement System 2SAM Medical Products Implements Voluntary Recall of its Accessory (Axilla) Strap for the SAM Junctional Tourniquet. 2
... to Phase 3; Eligible for Accelerated Approval; ... Global Regulatory Plan Expected by Year End, CRANBURY, ... a biopharmaceutical company developing small molecule,orally-administered pharmacological chaperones for ... has successfully completed an End,of Phase 2 meeting for ...
... Rare Genetic Disorder in,Children--, PHILADELPHIA, July 31 ... levels of blood sugar in animals genetically,engineered to ... in humans, it could become an innovative medicine ... devastating genetic,disease in which insulin levels become dangerously ...
Cached Medicine Technology:Amicus Therapeutics Announces Successful Completion of End of Phase 2 Meeting With FDA for Amigal in Fabry Disease 2Amicus Therapeutics Announces Successful Completion of End of Phase 2 Meeting With FDA for Amigal in Fabry Disease 3Amicus Therapeutics Announces Successful Completion of End of Phase 2 Meeting With FDA for Amigal in Fabry Disease 4Treatment Corrects Severe Insulin Imbalance in Animal Studies 2Treatment Corrects Severe Insulin Imbalance in Animal Studies 3
(Date:9/2/2014)... 02, 2014 The Quantum Group, ... Quantum Innovations, Inc . (QI), it has submitted ... MU2 Certification with a private IT security laboratory approved ... The platform has Meaningful Use 1 certification status (see ... approved and 15 pending patents. The accrediting organization has ...
(Date:9/2/2014)... public support for marijuana legalization in the U.S. has ... than other substances, such as alcohol. In January, President ... marijuana is more dangerous than alcohol. Despite the recent ... as compared to alcohol use are not well understood. ... Outcomes Associated with Drug Use among US High School ...
(Date:9/2/2014)... (PRWEB) September 02, 2014 At the ... Prosupps will be an exhibitor at the Las ... Rd, Las Vegas, NV 89109 Booth #374 Sept 19th ... to encourage healthy living through exercise, diet and supplementation. ... vision, and provide the tools for all Prosupps customers ...
(Date:9/2/2014)... Smile Squared, a well-known Buy One, Give ... a US-made toothbrush. For every toothbrush purchased, Smile Squared ... Squared was created by my wife and me after ... Cope, President of Smile Squared. “There, we saw children ... many of the same children didn't own a toothbrush. ...
(Date:9/2/2014)... Tuesday 2 September 2014: Digoxin may increase the ... by approximately 20%, according to results from the ROCKET ... Manesh Patel, director of interventional cardiology and catheterisation labs ... US. The findings suggest that caution may be needed ... studies are needed to confirm the observations. , Dr ...
Breaking Medicine News(10 mins):Health News:Grace Century’s EHR Project, The Quantum Group, Inc., Announces Submission for MU2 Certification 2Health News:Grace Century’s EHR Project, The Quantum Group, Inc., Announces Submission for MU2 Certification 3Health News:Grace Century’s EHR Project, The Quantum Group, Inc., Announces Submission for MU2 Certification 4Health News:Grace Century’s EHR Project, The Quantum Group, Inc., Announces Submission for MU2 Certification 5Health News:NYU study compares consequences of teen alcohol and marijuana use 2Health News:NYU study compares consequences of teen alcohol and marijuana use 3Health News:Prosupps, One of the Fastest Growing Supplement Companies, Celebrates a Success Milestone with Exhibiting at the 50th Annual 2014 Mr. Olympia’s Fitness & Performance Expo 2Health News:Smile Squared's Colorful Buy One, Give One Toothbrush Now Available in Schnucks Stores 2Health News:ROCKET AF trial suggests that digoxin increases risk of death in AF patients 2
... MISSISSAUGA, ON, May 13 /PRNewswire-FirstCall/ - Cipher Pharmaceuticals,Inc. ... Drug Application (NDA),has been submitted to the U.S. ... extended-release formulation of tramadol. In May 2007,the Company ... to its,NDA for CIP-TRAMADOL ER., Cipher,s revised ...
... May 13 Lumenis Inc., a global,developer, ... radiofrequency,devices for surgical, aesthetic, and ophthalmic applications, ... Enucleation of the Prostate (HoLEP),preceptor program that ... interested in learning and performing HoLEP. The ...
... Project proceeds despite non-compliance with California Environmental ... Quality ... Center (PHCMC) today went ahead with the planned expansion of its,Holy ... has upheld charges that the approval process was significantly flawed.,The groundbreaking ...
... 12 /PRNewswire-FirstCall/ - Med-Emerg International Inc.,(OTCBB - MDER), ... three months ended March 31, 2008 were $5.5 ... in 2007 (all amounts are $US unless,otherwise stated). ... interest and taxes (EBITDA) improved to $179K,from a ...
... TSX:,WHT) World Heart Corporation ("WorldHeart" or the "Corporation") ... Bulletin today advising it,is reviewing the eligibility for ... of WorldHeart under sections 709 and 710(a) of ... Company,s financial condition and,operating results, more specifically whether ...
... Institute (KGI),today announced that the May 17, 2008, commencement ... Applied Life Sciences student, Eric,Tan, and the unveiling of ... and proud of Eric,s achievement in becoming the,first graduate ... KGI,s senior,vice president for academic affairs, dean of faculty ...
Cached Medicine News:Health News:Cipher provides regulatory update for CIP-TRAMADOL ER 2Health News:Cipher provides regulatory update for CIP-TRAMADOL ER 3Health News:Lumenis Launches HoLEP Preceptor Program at American Urology Association 2008 Annual Meeting 2Health News:Lumenis Launches HoLEP Preceptor Program at American Urology Association 2008 Annual Meeting 3Health News:Providence Holy Cross Medical Center Ignores Community, Environmental Concerns With Planned Expansion of Mission Hills Facility 2Health News:Med-Emerg International Inc. reports improved income from continuing operations 2Health News:Med-Emerg International Inc. reports improved income from continuing operations 3Health News:WorldHeart Notified of TSX Delisting Review 2Health News:KGI 2008 Commencement Features First PhD Graduate, Biotech Painting 2
... The ImmunoWELL VZV IgG ... for the qualitative detection of ... (VZV). Test results are used ... status or infection. Immune status ...
... Test is an enzyme immunoassay (EIA) test ... human thyroglobulin and human thyroid peroxidase (microsome) ... is used as an aid in the ... disorders are characterized by detection of anti-thyroid ...
... ImmunoDOT Autoimmunity Screening Panel 1 is ... screening and detection of autoantibodies against ... SS-A/SS-B, RNP/Sm) in serum, and is ... diagnosis of systemic lupus erythematosus (SLE), ...
... Antibody (IgG) Test is an ... quantitative detection of antibodies to ... is used as an aid ... thrombosis in individuals with systemic ...
Medicine Products: